Frontiers in immunology · 2026
Synergy between immune system and antibiotics drives infection control in mice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Padmakumari Rajalekshmy G, Roy Ruchi, Mahmud Foyez, Dehari Deepa, Tesfaw Getnet, Thomas Christi, Soulika Athena M, Isseroff Roslyn Rivkah, Shafikhani Sasha H
Аннотация
BACKGROUND: Antibiotics and host immunity are traditionally viewed as independent defenses, with antibiotics reducing bacterial load to levels manageable by the immune system. Modeling studies, however, predict that synergy between these defenses is critical for infection control, but this has not been experimentally verified.
METHODS: We tested this concept using a Pseudomonas aeruginosa wound infection model in immunocompetent (C57BL/6) and immunocompromised (NSG) mice treated with systemic tobramycin.
RESULTS: In C57BL/6 mice, tobramycin-mediated bacterial killing increased pathogen-associated molecular patterns (PAMPs) - namely lipopolysaccharide (LPS) - which in turn amplified local inflammation, enhancing antibiotic efficacy in a manner largely dependent on neutrophils. In contrast, NSG mice failed to potentiate tobramycin bacterial killing to increase PAMPs and mount Tobramycin-induced boost in immune activation, resulting in reduced infection control. Importantly, topical PAMPs (LPS and N-formyl-methionyl-leucyl-phenylalanine (fMLP)) restored immune activation and improved infection control in NSG mice in a manner that was also dependent on neutrophil's function.
CONCLUSION: These findings provide direct experimental evidence that antibiotic efficacy requires synergy with host immunity. They highlight the therapeutic potential of augmenting innate immune activation to improve infection outcomes, particularly in immunocompromised patients.
METHODS: We tested this concept using a Pseudomonas aeruginosa wound infection model in immunocompetent (C57BL/6) and immunocompromised (NSG) mice treated with systemic tobramycin.
RESULTS: In C57BL/6 mice, tobramycin-mediated bacterial killing increased pathogen-associated molecular patterns (PAMPs) - namely lipopolysaccharide (LPS) - which in turn amplified local inflammation, enhancing antibiotic efficacy in a manner largely dependent on neutrophils. In contrast, NSG mice failed to potentiate tobramycin bacterial killing to increase PAMPs and mount Tobramycin-induced boost in immune activation, resulting in reduced infection control. Importantly, topical PAMPs (LPS and N-formyl-methionyl-leucyl-phenylalanine (fMLP)) restored immune activation and improved infection control in NSG mice in a manner that was also dependent on neutrophil's function.
CONCLUSION: These findings provide direct experimental evidence that antibiotic efficacy requires synergy with host immunity. They highlight the therapeutic potential of augmenting innate immune activation to improve infection outcomes, particularly in immunocompromised patients.